Psychedelic research shutdown

Psychedelic research shutdown was the abrupt end, by 1966, of nearly all sanctioned psychedelic research in the United States. It was more than a regulatory pause: the withdrawal of LSD supplies and the FDA’s stop-work orders dismantled a national research network just as its practitioners were disputing what counted as legitimate science, medicine, and spiritual experience. The work did not disappear. It continued in a small surviving institutional program and in underground practice, whose influence later crossed back into university research.

A challenge to psychiatric boundaries

The shutdown followed a growing conflict over what psychedelic therapy was supposed to be. Earlier models had been easier to accommodate within psychiatry: the psychotomimetic model treated drug effects as resembling mental illness, while psycholytic practice fitted the drugs into psychoanalysis as an aid to talking therapy. The psychedelic model proposed something more disruptive: a single high-dose session intended to produce a conversion-like experience, changing both the customary role of the patient and that of the therapist. Its therapeutic aim and compressed format challenged the profession’s established routines as well as its account of treatment.

The approach also blurred lines that academic psychiatry increasingly wanted kept distinct: religion and science, sickness and health, healer and sufferer. Charles Grob later described it as applied mysticism. Attention to set and setting, and to the therapist’s role in shaping the session, made the method seem uncomfortably close to shamanic practice. That unease coincided with the rise of the double-blind, placebo-controlled trial as the accepted standard for testing drugs. Psychedelic trials were difficult to blind because participants and guides could often tell whether psilocybin or a placebo had been administered; separating the drug’s effects from setting, therapist, and expectation was harder still. The very features practitioners considered central to treatment complicated the methods by which medicine sought to establish efficacy.

Professional criticism sharpened in the early 1960s. Roy Grinker, editor of the Archives of General Psychiatry, argued that researchers who took the drugs themselves and became absorbed in mystical experiences were disqualified as competent investigators. The next year he objected that investigators’ own experiences biased their conclusions. Other critics described an aura of magic around the drugs. The dispute was therefore not simply over whether the compounds had effects, but over whether research that engaged spirituality, altered experience, and the investigator’s participation could still claim scientific authority.

Withdrawal and the federal order

In April 1966, Sandoz withdrew LSD-25 from circulation, seeking distance from the controversy surrounding the drug. The company transferred most of its remaining stocks to the U.S. government. The withdrawal struck at the material basis of research: of roughly seventy programs then underway, many shut down after supplies became unavailable.

In May, Timothy Leary and Sidney Cohen testified at Senate hearings, defending psychedelic research and trying to distinguish legitimate medical use from the black market the government intended to suppress. Senator Robert F. Kennedy questioned why projects regarded as worthwhile six months earlier should no longer be considered worthwhile, and warned that banning medical use because of illicit use would cost the country a potentially helpful treatment. His intervention offered researchers a sympathetic hearing, but did not reverse the political momentum.

By October, the FDA had sent letters to about sixty psychedelic researchers across the country ordering them to stop their work. At the International Foundation for Advanced Study, psychologist James Fadiman received the letter just as he had finished dosing four participants in a problem-solving experiment. The participants were already lying in the next room as he read the notice. Fadiman and his colleagues agreed to treat the letter as if it had arrived the following day; the next day, the foundation’s program closed, along with virtually every other American program still operating. The juxtaposition was stark: an administrative decision arrived at the precise moment a research session was beginning, and a whole experimental enterprise ended between one day and the next.

The exception and the underground

One major program survived the closures: the Maryland Psychiatric Research Center at Spring Grove. Researchers including Stanislav Grof, Bill Richards, Richard Yensen, and Walter Pahnke continued work with psilocybin and LSD. Their studies addressed alcoholism, schizophrenia, and the existential distress of cancer patients. The program remained active until 1976, an exception whose continuation the book presents as unexplained. Former staff members rejected speculation that the center stayed open to provide therapy to powerful people in Washington or preserve privileged access to the drugs. They did confirm that its director, Albert Kurland, had strong federal connections and used them to keep the center operating and obtain LSD, including some from the government.

Closure did not end practice; it changed its conditions. Psychedelic therapy moved underground, continuing quietly and in secret. The underground guides later interviewed by the author traced professional lineages through figures including Timothy Leary, Stanislav Grof, Al Hubbard, and Leo Zeff. Zeff, who died in 1988, said that he had treated three thousand patients and trained 150 guides. His work helped codify practices such as strict confidentiality, a prohibition on sexual contact, and agreements governing conduct during sessions. The underground was not simply a hidden continuation of the old research programs: it preserved and adapted therapeutic knowledge outside legal institutions, where it could no longer be openly tested or authorized.

Knowledge carried forward

The separation between underground work and university research was never absolute. Myron Stolaroff argued that the psychedelic research revived in the late 1990s had developed partly from underground therapists’ anecdotal evidence as well as from first-wave studies in the 1950s and 1960s. Researchers at universities later sought advice from underground guides, including when the Johns Hopkins team investigated music in guided psilocybin sessions. At a 2010 conference in San Jose, James Fadiman called for a meeting of underground guides; he expected a handful and found a hundred. The gathering made visible a population and a body of practice that the formal shutdown had not erased.

The later revival resumed questions that earlier researchers had been forced to leave unfinished, but it also inherited the methodological and cultural difficulties that had helped isolate psychedelic therapy in the first place. At a later conference, former leaders of the American Psychiatric Association and the National Institute of Mental Health publicly recognized the promise of psychedelic-assisted psychotherapy, while cautioning that regulators would have difficulty evaluating a treatment that could not be cleanly separated from its context. The shutdown thus left a double legacy: a long interruption in sanctioned research, and an informal transmission of methods and experience that helped make renewed study possible. The boundary between science and spirituality, and between drug and administered experience, remained unsettled rather than closed.